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Understanding the epidemiology and clinical course of tuberculosis is hampered by the absence of a perfect test
for latent tuberculosis infection. The tuberculin skin test (TST) is widely used but suffers poor speciﬁcity in those
receiving the bacille Calmette-Gue´rin vaccine and poor sensitivity in individuals with human immunodeﬁciency
virus (HIV) infections. TST responses for a target population in Harare, Zimbabwe (HIV prevalence, 21%), recruited
in 2005–2006, were interpreted by using a separate calibration population in Harare, for which interferon-gamma
release assays (enzyme-linked immunosorbent spot (ELISpot)) results were also known. Statistical ﬁtting of the
responses in the calibration population allowed computation of the probability that an individual in the target
population with a given TST and HIV result would have tested ELISpot positive. From this, estimates of the
prevalence of tuberculosis infection, and optimal TST cutpoints to minimize misdiagnosis, were computed for
different assumptions about ELISpot performance. Different assumptions about the sensitivity and speciﬁcity of
ELISpot gave a 40%–57% prevalence of tuberculosis infection in the target population (including HIV-infected
individuals) and optimal TST cutpoints typically in the 10 mm–20 mm range. However, the optimal cutpoint for HIV-
infected individuals was consistently 0 mm. This calibration method may provide a valuable tool for interpreting
TST results in other populations.
enzyme-linked immunosorbent assay; HIV; tuberculin test; tuberculosis
Abbreviations: BCG, bacille Calmette-Gue´rin; ELISpot, enzyme-linked immunosorbent spot; HIV, human immunodeﬁciency virus;
IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection; TST, tuberculin skin test.
An estimated 9.27 million incident cases of tuberculosis
occurred in 2007, with 15% of those affected estimated to be
positive for human immunodeficiency virus (HIV) (1). From
a clinical perspective, diagnosis and treatment of latent tu-
berculosis infection (LTBI) is important because it reduces
the risk of progression and associated complications (2).
Equally, from a population perspective, estimating the prev-
alence of LTBI is important for evaluating the performance
of health policies and interventions. Diagnosing LTBI, how-
ever, remains a challenge. Until recently, LTBI diagnosis
relied on the tuberculin skin test (TST). The TST has low
specificity in individuals who have received the bacille
Calmette-Gue´rin (BCG) vaccine or been exposed to non-
tuberculous mycobacteria in the environment, and it shows
little or no reaction in some individuals, particularly the
immunocompromised (3, 4). Although estimating infection
burden for populations in sub-Saharan Africa is a priority
for tuberculosis control programs, high HIV prevalence,
widespread BCG vaccination, and environmental mycobac-
terial exposure make this task very challenging (3, 4).
Newer T-cell-based interferon-gamma release assays
(IGRAs) are superior to the TST in each of these instances
(5, 6). Currently, 2 methodological platforms are used to
measure interferon-gamma: a system based on enzyme-
linked immunosorbent spot (ELISpot) and a system based
on enzyme-linked immunosorbent assay. The results of
IGRAs are unaffected by BCG vaccination because these
assays use antigens not present in BCG. Evidence to date
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suggests that sensitivity of the platform based on ELISpot is
less affected by HIV coinfection than the platform based on
enzyme-linked immunosorbent assay (6–13). Thus, IGRAs
offer the potential to better estimate the prevalence of LTBI.
However, compared with TST, they remain expensive and
require blood samples and laboratory infrastructure often
unavailable in high-prevalence settings. Therefore, the
TST continues to be the more widely used.
In this paper, we propose and validate methods to inform
interpretation of TST results in populations with a high HIV
prevalence and high background levels of nontuberculosis
mycobacteria. Using data collected in Zimbabwe, we first
demonstrate—in a smaller calibration population in which
both the ELISpot-based IGRA and TST were performed—
that it is possible to define an optimal cutoff point for cross-
sectional HIV-stratified TST results, building on methods
used in comparable earlier studies (14, 15). Second, we
propose and apply a method validated in the calibration
population to a larger target population randomly selected
from a population-based survey, in which only the TST in-
duration results and HIV status are known, deriving optimal
cutoff points and LTBI prevalence estimates in this wider
population.
MATERIALS AND METHODS
Calibration population with IGRAs, TST, and HIV
measured
Study participants. A total of 536 participants were
recruited into a household contact case-control study be-
tween February 2002 and November 2004 within the frame-
work of a larger longitudinal study, described in detail
elsewhere (16), based on delivery of voluntary counseling
and testing for HIV and a package of primary health care
among factory workers in Harare, Zimbabwe. Recent house-
hold contacts of index tuberculosis cases were matched
against recent household contacts of controls chosen from
the same workplace as the cases. Controls had no recent
or current tuberculosis exposure. All were consenting indi-
viduals over the age of 10 years, and 86 of them were aged
10–15 years.
Excluding or including the index cases from the calibra-
tion study could each bias interpretation of results. Many
tuberculosis cases were at a late stage of HIV coinfection, so
their inclusion overrepresents the tuberculosis burden
among those infected with HIV. Moreover, the case-control
design of the study means that including them would over-
represent the prevalence in the general population. Their
exclusion may slightly underestimate LTBI prevalence in
the HIV-infected population, since some of those with LTBI
and HIV who would have been recruited will have pro-
gressed to disease. All analyses described below exclude
cases.
Tuberculin skin tests. A 2-step TST protocol was used
to increase sensitivity (17). Two units of RT-23 purified
protein derivative in Tween-80 (Statens Serum Institut,
Copenhagen, Denmark) were placed and read at 48–72
hours by using standard techniques. If the first reaction
was less than 10 mm, then a second TST was placed after
7–14 days. Only the first reaction was used for calibration to
ensure comparability with the single-step TSTs used in the
target population.
HIV testing. Blood was drawn from individuals older
than age 16 years for anonymous HIV testing when the first
TSTwas placed. Children aged 10–15 years were not tested
and were assumed to be HIV negative. Serum samples were
prepared and tested in parallel by using Determine (Abbott
Diagnostics, Wiesbaden, Germany) and Unigold (Trinity
Biotech, Dunblane, Scotland). No discordant results were
recorded. Voluntary counseling and testing was offered to
all participants older than age 15 years when blood was
drawn.
ELISpot assays. ELISpot assays were carried out as
described elsewhere (18). Duplicate wells contained no
antigen (negative control) or phytohemagglutinin (positive
control) (ICN Biomedical, Aurora, Ohio) at 5 lg/mL, or
13 pairs of duplicate wells each contained 1 of 13 peptide
pools incorporating 5–7 overlapping 15-mer peptides
spanning the length of early secretory antigenic target-6
and culture filtrate protein-10, on which the T-SPOT.TB
test (Oxford Immunotec Ltd., Abington, United Kingdom)
is based. The final concentration of each peptide was
10 lg/mL. ELISpot plates were sent to the Nuffield
Department of Clinical Medicine at John Radcliffe
Hospital in Oxford, United Kingdom, for automated spot
counting (AID-GmbH, Strassberg, Germany). Persons per-
forming and reading the assays were blind to all personal
identifiers and TST results.
Target community in which TST and HIV are
measured. Twelve percent of households in a study area
in western Harare (total population, 110,432 adults) were
randomly selected for inclusion in a population-based
cross-sectional survey of HIV and tuberculosis infection
and disease (19). Adults (aged 16 years or older) living
in selected households were asked to provide blood for
HIV testing (the Determine test, with all positive and
10% of negative results confirmed by the Unigold test)
and to have a TST conducted. TSTs used 2 units of PPD
RT-23 in Tween-80 and were read between 48 and 72 hours;
10% were reread by a second reader. Eighty-one percent of
individuals consented to HIV testing. A total of 8,057 in-
dividuals both provided an HIV specimen and had a TST
conducted and read. Treatment for tuberculosis infection is
not used in this population, and there were 91 active tuber-
culosis cases, only 18 of whom were receiving treatment at
the time of the survey. These cases were included in the
analysis. Antiretroviral therapy was very rare in the pop-
ulation, and data on counts of CD4-positive lymphocytes
were not available.
Mixture models for TST response
A mixture model composed of a point measure at 0 mm
(representing those who did not react to the skin test) and
a distribution for the nonzero reactions was fitted to the
measured TST indurations stratified by ELISpot and HIV
status from the calibration subpopulation. The probability of
measuring an induration of I mm given combined tubercu-
losis infection and HIV status s is thus
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pðIj sÞ ¼ pðsÞd0ðxÞ þ ð1 pðsÞÞf ðxj ls; rsÞ; ð1Þ
where d0ðxÞ is 1 when x¼ 0 and 0 otherwise, and pðsÞ is the
proportion who do not react to the skin test. The distribution
f(xjl, r) was chosen to be x:eðxlÞ2/2r2 normalized over the
positive integers. Cross-tabulation by ELISpot (Eþ vs. E)
and HIV (Hþ vs. H) status results in 4 possible outcomes:
s ¼ (EþH, EþHþ, EHþ, EH). Parameter estimation
was treated in a Bayesian framework, with uninformative (i.e.,
uniform) priors on the intervals [0,1], [0,30], and [0,30] for p,
l, and r, respectively, implemented by Metropolis-Hastings
Markov chainMonte Carlo. TheMarkov chain standard errors
were all less than 0.5%. Credible intervals for variables were
derived directly from their posterior distributions. Differences
between parameters were assessed by comparing the posterior
distributions; for example, for x and y, we drew 100,000 sam-
ples with replacement from each posterior distribution and
herein report the proportion of pairs in which x > y, denoted
pr(x > y).
Calculation of LTBI prevalence
The probability that someone with HIV status H and TST
result I would have tested positive to ELISpot (in the
absence of an actual ELISpot result) is
pðE ¼ þj I;HÞ ¼
pðIj E ¼ þ;HÞpðE ¼ þ;HÞ
pðIj E ¼ þ;HÞpðE ¼ þ;HÞ þ pðI;E ¼ ÞpðE ¼ ;HÞ ;
ð2Þ
where p(Ijs) is obtained from equation 1. Similar expres-
sions can be derived when either HIV status, a TST result, or
both, are missing, but less information entails a stronger
dependence on the parameters from the calibration study.
We assume that ELISpot is more informative than a TST
result in a way that does not depend on HIV status (techni-
cally, ELISpot status is a sufficient statistic in predicting
LTBI status). Then, the probability that an individual has
LTBI can be obtained, under assumptions about the proba-
bility of a false-negative (FN(E)) or false-positive (FP(E))
result using the ELISpot as a test for LTBI by
pðLTBIj I;HÞ ¼ð1 FPðEÞÞpðE ¼ þj I;HÞ þ FNðEÞ
ð1 pðE ¼ þj I;HÞÞ: ð3Þ
The population prevalence of LTBI, E(LTBI), is then
estimated as the mean of these probabilities:
EðLTBIÞ ¼ 1
N
X
I;H
pðLTBIj I;HÞnðI;HÞ; ð4Þ
where N is the total population size and n(I, H) is the number
of people with induration I and HIV statusH. The sensitivity
and specificity of ELISpot as a test for LTBI cannot be de-
termined in the absence of a ‘‘gold standard’’ test for LTBI.
We therefore performed our analysis for choices of 90% and
95% as the specificity of ELISpot as a test for LTBI and for
choices of 70%, 80%, and 90% as the sensitivity. For com-
parison with previous papers, we also show results assuming
perfect sensitivity and specificity, corresponding to ELISpot
as a gold standard test for LTBI.
Optimal cutoffs
Given a cutoff, c, to define a positive or negative TST
response, the mixture model (equation 1) determines the
probability of obtaining a false-negative (FN) or false-
positive (FP) result for ELISpot status by HIV status:
pðFNj c;HÞ ¼ pðE ¼ þ;HÞ þ ð1 pðE ¼ þ;HÞÞ
Fðcj E ¼ þ;HÞ;
pðFPj c;HÞ ¼ ð1 pðE ¼ ;HÞÞð1 Fðcj E ¼ ;HÞ;
ð5Þ
where F is the cumulative distribution function of f. We can
use knowledge of FN(E) and FP(E) for the ELISpot to ob-
tain the probability of a true false positive (TFP) and true
false negative (TFN) for LTBI from
TFNðc;HÞ ¼ ð1 FPðEÞÞpðFNj c;HÞ þ FNðEÞ
ð1 pðFNj c;HÞÞ
TFPðc;HÞ ¼ FPðEÞð1 pðFPj c;HÞÞ þ ð1 FNðEÞÞ
pðFPj c;HÞ:
ð6Þ
These probabilities can be weighted according to their
clinical consequences to form a disutility function, with c
chosen to minimize its expectation conditional on the prev-
alence of each disease state (refer to Bakir et al. (14);
Figure 1). If HIV status is unknown, we estimate the optimal
cutoff point as that for the mean prevalence of HIV.
RESULTS
Interpretation of TST using ELISpot in the calibration
population
BCG vaccination at birth is nearly universal in
Zimbabwe. In 1997, BCG coverage was 96.3%; BCG scars
were observed on 87% of the vaccinated children (20). In
our study population, 87% had BCG scars. HIV prevalence
was 19% among the 536 individuals for whom ELISpot
calibration was used. Thirty-six percent of this population
tested positive for LTBI with the ELISpot assay. The cali-
bration population is tabulated by HIVand ELISpot status in
Table 1.
Figure 2 shows the model fit to the TST data in the cal-
ibration population stratified by ELISpot and HIV status.
Among HIV-negative individuals, we found a distinct non-
zero distribution of TST for those who were ELISpot posi-
tive, peaking at approximately 20 mm. In this population,
there was only a small proportion of nonreactors (9.1%).
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There was a greater proportion of nonreactors among those
who were ELISpot negative compared with ELISpot posi-
tive (x ¼ 27.4% vs. y ¼ 9.1%, pr(x > y) <0.001). However,
we also found a substantial number of TST reactors in the
ELISpot-negative group, albeit with a lower peak induration
(approximately 10 mm), indicating that, among HIV-
negative persons, there remains a substantial number of non-
specific reactions in this population.
Among HIV-positive individuals, for those who were
ELISpot positive, we also found a clear peak in the distri-
bution of nonzero TST readings at approximately the same
induration as for HIV-negative persons (x ¼ 19.8 mm in
HIV-negative individuals vs. x ¼ 18.4 mm in HIV-positive
individuals, pr(x > y) ¼ 0.68). However, there was a greater
proportion of nonreactors in the ELISpot-positive/HIV-
positive group compared with the ELISpot-positive/HIV-
negative group (x ¼ 18.7% compared with y ¼ 9.1%,
pr(x < y) ¼ 0.08).
Table 2 shows the computed optimal cutoff points and
prevalences for this population stratified by HIV status. In
the HIV-positive population, assuming suboptimal perfor-
mance of ELISpot resulted in optimal cutoff points of
0 mm. In contrast, in the HIV-negative population, the
optimal cutoff points were always greater than zero,
with larger values for more optimistic assumptions about
ELISpot performance.
Prevalence of LTBI and optimal cutoff points in the
target population
The HIV prevalence among those tested was 21%, and we
found no significant differences in age or gender between
those who consented to HIV testing and those who did not.
Figure 3 shows the TST histograms for the target population
stratified by HIV status. Of note is the complete absence of
distinct peaks associated with LTBI and exposure to non-
tuberculosis mycobacteria or BCG vaccination. Mirror or
mixture methods are therefore of limited value in this set-
ting. The proportion of nonreactors (0 mm) estimated to be
latently infected did not differ by HIV status (x ¼ 31.7% in
HIV-positive individuals vs. y ¼ 32.8% in HIV-negative
individuals, pr(x > y) ¼ 0.59). Although the mean nonzero
reaction size for LTBI-positive individuals who are coin-
fected with HIV was marginally lower than for those who
are not (x ¼ 12.3 mm in HIV-negative individuals vs. y ¼
11.9 mm in HIV-positive individuals, pr(x > y) ¼ 0.89), the
far larger effect of HIV infection on the observed patterns is
to significantly increase the proportion of nonreactors (x ¼
30.5% in HIV-positive individuals vs. y ¼ 17.9% in HIV-
negative individuals, pr(x < y) < 0.001).
The estimated prevalence of LTBI in HIV-positive indi-
viduals is similar to that in HIV-negative individuals. It
Table 1. ELISpot and HIV Prevalence in the Calibration Population
of Zimbabwe Recruited in 2002–2004a
Proportion Who Are % No.
HIVþ, ELISpotþ 6 30
HIVþ, ELISpot 13 72
HIV, ELISpotþ 30 163
HIV, ELISpot 51 271
HIVþ 19 102
Abbreviations: ELISpot, enzyme-linked immunosorbent spot; HIV,
human immunodeﬁciency virus.
a The HIV prevalence in the target population was 21%.
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Figure 1. Sensitivity (circles) and speciﬁcity (crosses) of the tuberculin skin test with different cutoffs as a test for enzyme-linked immunosorbent
spot positivity in the calibration population of Zimbabwe recruited in 2002–2004; tuberculosis cases were excluded.
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ranged between 45% and 57% depending on the assumption
about ELISpot sensitivity and specificity as a test for LTBI
(Table 3).
Based on these estimates, the optimal cutoff points for
TST are shown in Table 3. Whereas cutoffs in the HIV-
negative and general populations varied between 9 mm
and 24 mm depending on the assumptions about ELISpot
performance, in the HIV-positive population, optimal cutoff
points were consistently determined as 0 mm, demonstrat-
ing the difficulty of interpreting the TST responses in HIV-
positive populations.
DISCUSSION
In a setting of high HIV prevalence, widespread BCG
vaccination, and the high prevalence of nonspecific tuber-
culin sensitization from environmental mycobacterial expo-
sure typical of tropical and subtropical Africa (21), we used
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Figure 2. Mixture model ﬁt to measure the tuberculin skin test indurations stratiﬁed by human immunodeﬁciency virus (HIV) infection and
enzyme-linked immunosorbent spot (ELISpot) response status in the calibration population of Zimbabwe (recruited in 2002–2004): A) HIV negative
and ELISpot negative, B) HIV positive and ELISpot negative, C) HIV negative and ELISpot positive, D) HIV positive and ELISpot positive.
Table 2. Estimated LTBI Prevalence and OCPs in the Calibration Population of Zimbabwe Recruited in 2002–2004a
Assumed Properties
of ELISpot as a Test
for LTBI
LTBI
Prevalence, %
All HIV1 HIV2
Sensitivity,
%
Speciﬁcity,
%
All HIV1 HIV2
OCP,
mm
Sensitivity,
%
Speciﬁcity,
%
OCP,
mm
Sensitivity,
%
Speciﬁcity,
%
OCP,
mm
Sensitivity,
%
Speciﬁcity,
%
70 90 52 48 53 10 68 52 0 65 67 11 69 48
80 90 45 41 46 14 60 63 0 71 67 15 57 62
90 90 39 34 40 19 41 79 15 49 83 20 39 77
70 95 53 49 54 9 70 51 0 65 70 10 72 46
80 95 47 42 48 13 63 62 0 71 70 14 61 60
90 95 41 35 42 17 53 72 11 60 79 11 52 70
100 100 36 29 38 19 43 81 15 53 87 20 41 79
Abbreviations: ELISpot, enzyme-linked immunosorbent spot; HIV, human immunodeﬁciency virus; LTBI, latent tuberculosis infection; OCP,
optimal cutpoint.
a Results are shown for different assumptions about the sensitivity and speciﬁcity of ELISpot as a test for LTBI. OCPs are shown combined and
by HIV status together with their speciﬁcity and sensitivity.
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ELISpot results from a smaller-calibration population to
optimize interpretation of TST for diagnosing LTBI in
a larger population to predict 1) the probability that some-
one with a given TST and HIV status would have LTBI and
2) the population prevalence of LTBI. To our knowledge,
this work represents the first attempt to use IGRAs to cali-
brate TST interpretation in a population with a high preva-
lence of HIV and when traditional mixture or mirror
methods are inapplicable because of the distribution of
TST indurations.
Standard TST histograms are depicted as being composed
of 3 distributions of individuals: those who do not react;
cross-reactors who are not infected but have a small, non-
zero mode; and the larger mode of those infected with tu-
berculosis (3, 15). When peaks due to cross-reactors and
those with LTBI are clearly distinct, a cutoff for a positive
reading can be chosen by eye for the population and used to
estimate LTBI prevalence. When histograms lack this clas-
sic ‘‘double hump,’’ further information is needed to inform
their interpretation. Here, the extra data are results from
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Figure 3. Histograms of tuberculin skin test indurations for the target population of Zimbabwe (recruited in 2002–2004) stratiﬁed by human
immunodeﬁciency virus (HIV) infection status: A) HIV infected, B) HIV uninfected. Dark gray: the proportion at each induration predicted to have
a latent tuberculosis infection (LTBIþ); light gray: the proportion at each induration predicted to be free of latent tuberculosis infection (LTBI). The
choice of enzyme-linked immunosorbent spot properties was as follows: sensitivity ¼ 70%, speciﬁcity ¼ 90%.
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a calibration study in the same region, which included
ELISpot results. The shape of the TST response probability
was fitted, stratified by ELISpot and HIV status, and the
proportion that each stratum contributes to the TST histo-
gram of the target population was calculated. Doing so
yielded an estimate of the prevalence of ELISpot positivity
and enabled us to predict the probability that someone with
a given TST would have tested positive by ELISpot.
Because the specificity and sensitivity of ELISpot are
unlikely to be equal, the number of individuals with LTBI
who are missed is unlikely to be equal to the number of
LTBI-negative individuals mistakenly classified as positive,
which means that LTBI prevalence estimates must be scaled
to take into account the specificity and sensitivity of
ELISpot. We considered a range of plausible error rates,
and we made all our assumptions about test performance
explicit. As more information about the performance and
prognostic value of ELISpot emerges (22–24), these preva-
lence estimates can be refined. When comparing preva-
lences in a population before and after interventions, the
important point is to use consistent criteria. For most as-
sumptions that were considered, our model produced LTBI
prevalence estimates for the general adult population in the
expected range of 40%–56% (25), giving some degree of
confidence in this approach. This prevalence compares with
an LTBI prevalence of 52% from a cutpoint approach,
regarding all individuals with indurations greater than or
equal to 10 mm as infected (in line with guidelines (26)).
Our analysis was not intended to distinguish active tubercu-
losis disease from LTBI: neither the IGRA nor the TST
effectively discriminates between these states, and indeed
we retained in our analysis the relatively small number
(n = 91) of participants found to have active, prevalent
tuberculosis disease.
Although, in terms of epidemiologic considerations, us-
ing an infection status determined by a cutoff wastes the
available information, such criteria are clinically useful
for individual patient decisions. We calculated cutpoints that
are optimal in the sense of minimizing the expected rate of
misdiagnosis for individuals chosen randomly from the pop-
ulation. The optimal cutoff points for HIV-negative individ-
uals and for the general population varied unsurprisingly:
more-optimistic assumptions about ELISpot performance
gave higher optimal cutoff points. However, for most sce-
narios, the optimal cutoff for HIV-positive individuals was
0 mm—the probability of misdiagnosis was minimized in
HIV-positive individuals by always considering them to be
infected with tuberculosis. The 0-mm optimal cutoff point
for the HIV-infected population reflects the increase in non-
reactors described above, with low cutoffs here sacrificing
sensitivity without a sufficiently compensatory increase in
specificity. Disutilities that weight missed infections more
strongly would therefore strengthen this result.
It is known that chemoprophylaxis against tuberculosis
disease has a larger protective effect in HIV-infected indi-
viduals who are TST positive than it does in HIV-infected
individuals who are TST negative (27). This finding can be
reconciled with our results, however, because diagnosis
should be distinguished from prognosis. Our 0-mm cutpoint
is optimal in the sense of minimizing the chances ofT
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misassigning tuberculosis infection status in HIV-positive
persons. If a positive TST result in HIV-positive individuals
correlates with impending progression, it still has value in
terms of choosing who should receive prophylactic
treatment.
Our target population was not selected on the basis of
recent tuberculosis exposure and thus included persons re-
cently infected with LTBI as well as persons who may have
been infected for many years. This is in contrast to the study
of child household contacts conducted in Istanbul, Turkey,
where there was a greater concordance between positive
ELISpot results and high TST reactions (14). It is well de-
scribed that the specificity of TST has considerable geo-
graphic variation because of differences in the distribution
of nonspecific tuberculin reactions, reflecting variable envi-
ronmental mycobacterial exposure (21, 28). Notably, there
was more evidence of such sensitization in the Zimbabwean
participants compared with a lower frequency of small, but
nonzero TST reactions in the children in the Turkish study.
BCG vaccination coverage is also higher in Zimbabwe than
in Turkey. Lastly, there is the possibility that IGRA sensi-
tivity may wane with time after infection, as hypothesized
by Arend et al. (29) to explain similar discrepancies between
TST and IGRA positivity in those with high indurations.
Note that our estimates of LTBI prevalence were not
greatly affected by those with TST indurations not consid-
ered infected because of the small numbers involved. Con-
sidering all those with a TST 15 or 18 mm as infected
increased prevalence estimates by no more than 3%, and the
range of prevalences estimated remained 40%–60%.
A major limitation of this study was that the calibration
population was not a subset of the larger TST study but was
instead taken from factory employees and their households.
The age distributions of the 2 populations were similar
(although the sex ratio of women to men in the target
population was closer to 60:40 compared with 50:50 in
the calibration study) and the populations were from the
same town, but they were not matched in any formal sense.
It is important that calibration and target populations be well
matched in terms of CD4þ lymphocyte counts in those
infected with HIV, since the performance of both the TST
(30) and the ELISpot (7) are affected by this factor. Given
a falling HIV incidence in Zimbabwe, it is possible that the
target study, which was conducted 2 years after the calibra-
tion study, may have differed slightly in the CD4þ lympho-
cyte counts among HIV-infected persons. Moreover, the
TST results accompanying the ELISpot responses were sub-
optimal, with more digit preference than in the larger gen-
eral population HIV-TST survey (Figure 2 compared with
Figure 3). It is possible that the accuracy of the subsequent
analysis was limited by these 2 factors.
Our approach is different from that used recently by Pai
et al. (15). Those authors used 2 approaches to estimate
LTBI prevalence in a single population for whom there were
data from TSTs and IGRAs. The first method was to fit
a mixture model to the TST results alone to obtain a preva-
lence estimate. The second method introduced a cutoff for
the TST results, yielding 4 test counts for the population:
(TST, IGRA) ¼ (þ,þ), (þ,), (,þ), (,). These counts
were interpreted in a Bayesian way by using a latent class
analysis to update prior assumptions about the sensitivity
and specificity of the tests and yield an estimate of LTBI
prevalence. We used the full range of TST results (and HIV
results) informed by additional IGRA results in a calibration
population and for a range of assumptions about IGRA test
characteristics.
Although our results are specific to this population and
cannot be generalized, our methods can be applied to other
populations. Distinguishing the underlying Mycobacterium
tuberculosis distribution from nonspecific TST reactions has
become increasingly difficult in non-specifically-sensitized
populations in which tuberculosis control efforts have suc-
ceeded in reducing the prevalence of LTBI, as in Tanzania
(31). Nested IGRA-TST calibration substudies have the po-
tential to identify the M. tuberculosis mode with more con-
fidence than would otherwise be possible and need not be
applied to the entire population being included in a TST
survey.
The need for more accurate indicators of tuberculosis
transmission rates is especially pressing in high-HIV-
prevalence populations, where rising tuberculosis incidence
rates do not seem to correlate well with tuberculosis trans-
mission trends (31, 32). Moving tuberculosis control for-
ward in the era of HIV requires effective monitoring of
populations as well as better diagnosis and treatment, and
practical ways to harness the full potential of newer tests for
LTBI must be developed and implemented as widely as
possible. We think that methods such as ours and those of
Bakir et al. (14), which use IGRA studies to help inform
interpretation of TST surveys, will be invaluable in gener-
ating the necessary evidence base to further our understand-
ing of tuberculosis epidemiology in the 21st century.
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